N-ACETYL CYSTEINE IN SCHIZOPHRENIA RESISTANT TO CLOZAPINE: A DOUBLE-BLIND RANDOMISED PLACEBO-CONTROLLED TRIAL TARGETING NEGATIVE SYMPTOMS

Grant number: 1098442 | Funding period: 2016 - 2019

Completed

Abstract

Many patients with schizophrenia remain treatment resistant even after “last resort” medications like clozapine. This proposal will conduct a novel multi-site randomised placebo controlled trial of adjunctive N-acetyl cysteine in patients with clozapine resistant schizophrenia. Treatment efficacy will be examined at 8, 26 and 52 weeks.

Related publications (4)

Scholarly works icon

N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms

Erica Neill, Susan L Rossell, Caitlin Yolland, Denny Meyer, Cherrie Galletly, Anthony Harris, Dan Siskind, Michael Berk, Kiymet Bozaoglu, Frances Dark, Olivia M Dean, Paul S Francis, Dennis Liu, Andrea Phillipou, Jerome Sarris, David J Castle

2022-07-20

BACKGROUND AND HYPOTHESIS: Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, yet a significant ..

Scholarly works icon

Does the clozapine/norclozapine ratio predict cognitive performance in patients with clozapine-resistant schizophrenia?

Urska Arnautovska, Erica Neill, Susan L Rossell, Caitlin Yolland, Cherrie Galletly, Anthony Harris, David J Castle, Dan Siskind

2021-12-07

Scholarly works icon

Improvement of cognitive function in schizophrenia with N-acetylcysteine: A theoretical review

Caitlin OB Yolland, Andrea Phillipou, David J Castle, Erica Neill, Matthew E Hughes, Cherrie Galletly, Zoe M Smith, Paul S Francis, Olivia M Dean, Jerome Sarris, Dan Siskind, Anthony WF Harris, Susan L Rossell

2020-02-01

Objectives: Schizophrenia is a debilitating psychiatric illness associated with positive and negative symptoms as well as signific..

Scholarly works icon

N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms

Susan L Rossell, Paul S Francis, Cherrie Galletly, Anthony Harris, Dan Siskind, Michael Berk, Kiymet Bozaoglu, Frances Dark, Olivia Dean, Dennis Liu, Denny Meyer, Erica Neill, Andrea Phillipou, Jerome Sarris, David J Castle

2016-09-15

BACKGROUND: Clozapine is an effective treatment for a proportion of people with schizophrenia (SZ) who are resistant to the benefi..

University of Melbourne Researchers